D 6428

Drug Profile

D 6428

Latest Information Update: 23 Jan 2004

Price : $50

At a glance

  • Originator Celltech Group; Penwest Pharmaceuticals
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 23 Jan 2004 Discontinued - Phase-I for Pain in USA (PO)
  • 23 Jan 2004 Discontinued - Phase-I for Pain in United Kingdom (PO)
  • 15 Dec 2000 Phase-I clinical trials for Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top